EXTENSIONS of indications registrations for Dec have been posted by the Therapeutic Goods Administration on its website.
Pfizer's vasomotor symptoms treatment Duavive (conjugated estrogens/bazedoxifene acetate), Janssen-Cilag's Imbruvica/Janssen Ibrutinib (ibrutinib), Johnson and Johnson's Evicel (fibrinogen/thrombin) and Ferring's Nocdurna (desmopressin) were highlighted.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Dec 16
